Across the peptide, compounding, telehealth, wellness, and research industries, businesses are reporting a troubling pattern: terminated merchant accounts, frozen funds, rejected applications, excessive reserves, and sudden restrictions tied to peptide-related products. These actions can financially cripple a lawful business—sometimes without a meaningful explanation, individualized review, or opportunity to appeal. The time has come to determine whether these were independen